Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

AstraZeneca
Merck
Mallinckrodt
Medtronic
Express Scripts
Harvard Business School

Last Updated: December 3, 2022

Details for New Drug Application (NDA): 207923


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


NDA 207923 describes SEEBRI, which is a drug marketed by Novartis and is included in one NDA. There are two patents protecting this drug. Additional details are available on the SEEBRI profile page.

The generic ingredient in SEEBRI is glycopyrrolate. There are seventeen drug master file entries for this compound. Forty-seven suppliers are listed for this compound. Additional details are available on the glycopyrrolate profile page.
Summary for 207923
Tradename:SEEBRI
Applicant:Novartis
Ingredient:glycopyrrolate
Patents:2
Formulation / Manufacturing:see details
Medical Subject Heading (MeSH) Categories for 207923

Profile for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:POWDER;INHALATIONStrength15.6MCG/INH
Approval Date:Oct 29, 2015TE:RLD:Yes
Patent:See Plans and PricingPatent Expiration:Oct 20, 2028Product Flag?YSubstance Flag?Delist Request?
Patent:See Plans and PricingPatent Expiration:Oct 11, 2028Product Flag?YSubstance Flag?Delist Request?

Expired US Patents for NDA 207923

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis SEEBRI glycopyrrolate POWDER;INHALATION 207923-001 Oct 29, 2015 See Plans and Pricing See Plans and Pricing
Novartis SEEBRI glycopyrrolate POWDER;INHALATION 207923-001 Oct 29, 2015 See Plans and Pricing See Plans and Pricing
Novartis SEEBRI glycopyrrolate POWDER;INHALATION 207923-001 Oct 29, 2015 See Plans and Pricing See Plans and Pricing
Novartis SEEBRI glycopyrrolate POWDER;INHALATION 207923-001 Oct 29, 2015 See Plans and Pricing See Plans and Pricing
Novartis SEEBRI glycopyrrolate POWDER;INHALATION 207923-001 Oct 29, 2015 See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKesson
AstraZeneca
Medtronic
Baxter
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.